Lynch Syndrome Clinical Trials

Find Lynch Syndrome Clinical Trials Near You

Lynch Syndrome Integrative Epidemiology and Genetics (LINEAGE)

Status: Recruiting

Location: See all (2) locations...

Study Type: Observational

SUMMARY

The vision of the Lynch syndrome INtegrative Epidemiology And GEnetics (LINEAGE) Consortium is to collaboratively improve the lives and longevity of individuals and families with Lynch syndrome. The mission of the LINEAGE Consortium is to collaboratively improve Lynch syndrome care through high-quality research. This consortium will provide intellectual and infrastructure support to facilitate development of research questions, collection of standardized data and biospecimens, support of grant applications, and generation of collaborative manuscripts. Our aims are to: I. Establish a prospective cohort of individuals with Lynch syndrome II. Collect standardized longitudinal clinical and biosample data to elucidate Lynch Syndrome epidemiology and gene-host interactions III. Promote intervention trials to improve cancer prevention and early detection in Lynch Syndrome

Eligibility

Participation Requirements

Sex: All

Minimum Age: 18

Healthy Volunteers: f

View:

• • Adults age over 18 years

‣ Eligible patients must have at least one variant of uncertain significance (VUS), pathogenic or likely pathogenic variant (PV/LPV) in MLH1, MSH2, MSH6, PMS2, or EPCAM, which will be confirmed by genetic testing results (obtained as part of routine care) and a review of the variant in ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/).

⁃ Individuals who are an obligate carrier of a LS PV/LPV that is confirmed in the family.

Locations

United States

Colorado

University of Colorado

RECRUITING

Aurora

Illinois

University of Chicago

NOT_YET_RECRUITING

Chicago

Contact Information

Primary

Swati G Patel, MD, MS

swati.patel@cuanschutz.edu

3032170731

Backup

Sonia Kupfer, MD

Time Frame

Start Date: 2024-10-01

Estimated Completion Date: 2054-12-31

Participants

Target number of participants: 5000

Treatments

Pateints with a germline variant in a mismatch repair gene

Individuals with germline genetic testing results showing a pathogenic, likely pathogenic or variant of uncertain significance in MLH1, MSH2, MSH6, PMS2 or EPCAM.

Related Therapeutic Areas

Lynch Syndrome

Sponsors

Collaborators: University of California, San Diego, University of Rochester, University of Miami, University of Arizona, Dana-Farber Cancer Institute, University of Michigan, University of Wisconsin, Madison, The Cleveland Clinic, Loma Linda University, University of Pittsburgh, Virginia Mason Hospital/Medical Center, University of Kansas, Kaiser Permanente, University of Pennsylvania, City of Hope National Medical Center, University of North Carolina, University of Manitoba, MedStar Health, Johns Hopkins University, University of Alabama at Birmingham, Ohio State University, University of Chicago

Leads: University of Colorado, Denver

This content was sourced from clinicaltrials.gov

Similar Clinical Trials

View All